Search

Your search keyword '"Pacilli, L"' showing total 89 results
Start Over Author "Pacilli, L"
89 results on '"Pacilli, L"'

2. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, M.T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, S.F., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, A.M., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, E.M., Luppi, M., Marasca, R., Pogliani, E.M., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, M.C., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, A.M., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., D'Emilio, A., Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., and Rosti, G.

Published
2015
Full Text
View/download PDF

3. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, MT., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, SF., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, AM., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, EM., Luppi, M., Marasca, R., Pogliani, EM., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, MC., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, AM., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., and DʼEmilio, A.

Published
2015
Full Text
View/download PDF

7. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C

Subjects
DIAGNOSED CHRONIC-PHASE, Oncology, Male, Cancer Research, Time Factors, bcr-abl, Fusion Proteins, bcr-abl, Antineoplastic Agent, Hematology, Anesthesiology and Pain Medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Cumulative incidence, Young adult, Chronic, Aged, 80 and over, Leukemia, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, CML WORKING PARTY, 3-YEAR FOLLOW-UP, EUROPEAN LEUKEMIANET, 400 MG, Myeloid leukemia, Middle Aged, Prognosis, Treatment Outcome, Retreatment, Imatinib Mesylate, Female, Tyrosine kinase, Human, medicine.drug, Adult, medicine.medical_specialty, Time Factor, Adolescent, Prognosi, Protein Kinase Inhibitor, Socio-culturale, Antineoplastic Agents, Treatment results, Follow-Up Studie, Young Adult, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Fusion Proteins, Imatinib, Follow-Up Studies, Surgery, Imatinib mesylate, BCR-ABL Positive, business, Myelogenous
Abstract

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.

Published
2015

8. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, D'Emilio, A., Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, and D'Emilio, A.

Abstract

Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. Patients and methods: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CMLWP over a 40-year period. Results: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). Conclusions: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome.

Published
2015

9. Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials

Author

Pagano, L., Pulsoni, Alessandro, Tosti, M. E., Caramatti, C., Cerri, R., Falcucci, P., Fazi, P., Fianchi, L., Martino, B., Mattei, D., Offidani, M., Pacilli, L., Pogliani, E. M., Rotoli, B., Specchia, G., Visani, G., Vignetti, Marco, Voso, M. T., Leone, G., Mandelli, Franco, Gimema, Pagano, L, Pulsoni, A, Tosti, M, Caramatti, C, Cerri, R, Falcucci, P, Fazi, P, Fianchi, L, Martino, B, Mattei, D, Offidani, M, Pacilli, L, Pogliani, E, Rotoli, B, Specchia, G, Visani, G, Vignetti, M, Voso, M, Leone, G, and Mandelli, F

Subjects
Male, Adult, Cancer Research, Pediatrics, medicine.medical_specialty, Adolescent, antineoplastic combined chemotherapy protocols, neoplasms, Acute Disease, Aged, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Female, Humans, Leukemia, Myeloid, Middle Aged, Neoplasms, Second Primary, Remission Induction, Treatment Failure, Treatment failure, Remission induction, cohort studies, hemic and lymphatic diseases, medicine, humans, Antineoplastic Combined Chemotherapy Protocol, Adult patients, acute disease, adolescent, adult, adverse effects, aged, chemically induced, drug therapy, female, leukemia, male, middle aged, myeloid, remission induction, second primary, treatment failure, business.industry, Adult Acute Myeloid Leukemia, Hematology, Oncology, Second Malignancy, Cohort Studie, business, Settore MED/15 - Malattie del Sangue, After treatment, Cohort study, Human
Abstract

Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials

Published
2004

11. Occurence of pleural effusions during dasatinib treatment in elderly chronic myelogenous leukemia patients

Author

Latagliata, R., Breccia, M., Stagno, F., Luciano, L., Gozzini, A., Annunziata, M., Matteis, S., Albano, F., Ulisciani, S., Pregno, P., Pacilli, M., Abruzzese, E., Martino, B., Tiribelli, M., Avanzini, P., Pacilli, L., Paolo VIGNERI, Fabbricini, R., Russo Rossi, A., Sica, S., Vitolo, U., Montefusco, E., Fava, C., Ferrara, F., Santini, V., Pane, F., Francesco Di Raimondo, and Alimena, G.

Published
2009

12. La scabbia: una parassitosi emergente

Author

Sancin, A. M., Ensabella, F., Pacilli, L., Piraccini, B. M., Raitano, A., Viotti, P. L., Vitali, Matteo, and Agolini, G.

Published
2005

13. Risk of low bone density in women attending menopause clinics in Italy

Author

DE ALOYSIO, D, DI DONATO, P, Giulini, Na, Modena, B, Cicchetti, G, Comitini, G, Gentile, G, Cristiani, P, Careccia, A, Esposito, E, Gigli, C, Mandruzzato, G, Petraglia, F, Bertelli, F, DEL FRATE, G, Garofalo, S, Marino, L, Costa, Mr, Quaranta, S, Bossi, Cm, Amantea, P, Omodei, U, Vaccari, M, Luerti, M, Repetti, F, Zandonini, G, Raspagliesi, F, Dolci, F, Zacchi, V, Bennici, S, Polizzotti, G, Bottino, S, Raffaelli, F, Minervini, C, Colombo, D, Belloni, C, Viani, A, Cecchini, G, Winkler, S, Samaja, Ba, Pasinetti, E, Penotti, M, Malanetto, C, Massobrio, M, Campagnoli, C, Dolfin, G, Tartaglino, P, Mossotto, D, Pesando, P, Pacilli, L, Rattazzi, Pd, Arisi, E, Gamper, M, Salvatores, D, Bocchin, E, Stellin, G, Meli, G, Azzini, V, Tirozzi, F, Buoso, G, Fraioli, R, Marsoni, V, Cetera, C, Sposetti, R, Bellati, U, Angeloni, C, Buonerba, M, Garzarelli, S, Santilli, C, Mucci, M, DI NISIO, Q, Falasca, L, Ferrante, D, Cirese, E, Todaro, Pa, Romanini, C, Spagnuolo, L, Lanzone, A, Donadio, C, Fabiani, M, Baldaccini, E, Votano, S, Serra, Gb, Bellardini, P, Massacesi, L, Donini, G, Genazzani, Ra, Scarselli, G, Curiel, P, DE LEO, V, Melani, A, D'Ancona, Vl, Giarre, G, DI GIOIA, E, Ciccarelli, P, Sarti, Cd, Balsotti, G, Pupita, P, Mincigrucci, M, Spadafora, A, Santeufemia, G, D'Andrea, A, Chiantera, A, Montemagno, U, Staiano, S, Arienzo, R, Pastore, Ar, Tamburrino, A, Colacurci, A, Izzo, S, Zumpano, N, Pascarella, A, DE SILVIO MG, DI PRISCO, L, Lauda, N, Sorrentino, O, Agrimi, C, Casarella, G, Pisaturo, G, Senatore, G, Ruccia, G, Fasolino, A, Tropea, P, Stigliano, Cm, Giannice, C, Vadala, P, Coco, A, Lombardo, R, Barese, G, Masciari, G, Pirillo, P, Gioffre, T, Ferruccio, C, Agostinelli, D, Tonti, Gc, Scopelliti, A, Schonauer, S, Bongiovanni, F, Tinelli, F, Poddi, Er, Scarpello, F, Colonna, L, Fischetti, G, Doria, R, Trombetta, G, Cocca, Eb, Carone, D, Nocera, F, Giambanco, V, Giannola, C, Graziano, R, Mezzatesta, M, Vegna, G, Giannone, G, Palumbo, G, Cancellieri, Francesco, Mondo, A, Cordopatri, A, Carrubba, M, Mazzola, V, Ettore, G, D'Asta, S, DI LIBERTO, P, Massacesi, A, DE ALOYSIO, P, Ognissanti, F, Gambacciani, A, Graziottin, A, Baldi, C, Colacurci, N, and Parazzini, F.

Published
2002

15. General and medical factors associated with hormone replacement therapy among women attending menopause clinics in Italy

Author

DE ALOYSIO, D, DI DONATO, P, Giulini, Na, Modena, B, Cicchetti, G, Comitini, G, Gentile, G, Cristiani, P, Careccia, A, Esposito, E, Gigli, C, Mandruzzato, G, Petraglia, F, Bertelli, F, DEL FRATE, G, Garofalo, S, Marino, L, Costa, Mr, Quaranta, S, Bossi, Cm, Amantea, P, Omodei, U, Vaccari, M, Luerti, M, Repetti, F, Zandonini, G, Raspagliesi, F, Dolci, F, Zacchi, V, Bennici, S, Polizzotti, G, Bottino, S, Raffaelli, F, Minervini, C, Colombo, D, Belloni, C, Viani, A, Cecchini, G, Winkler, S, Samaja, Ba, Pasinetti, E, Penotti, M, Malanetto, C, Massobrio, M, Campagnoli, C, Dolfin, G, Tartaglino, P, Mossotto, D, Pesando, P, Pacilli, L, Rattazzi, Pd, Arisi, E, Gamper, M, Salvatores, D, Bocchin, E, Stellin, G, Meli, G, Azzini, V, Tirozzi, F, Buoso, G, Fraioli, R, Marsoni, V, Cetera, C, Sposetti, R, Bellati, U, Angeloni, C, Buonerba, M, Garzarelli, S, Santilli, C, Mucci, M, DI NISIO, Q, Falasca, L, Ferrante, D, Cirese, E, Todaro, Pa, Romanini, C, Spagnuolo, L, Lanzone, A, Donadio, C, Fabiani, M, Baldaccini, E, Votano, S, Serra, Gb, Bellardini, P, Massacesi, L, Donini, G, Genazzani, Ra, Scarselli, G, Curiel, P, DE LEO, V, Melani, A, D'Ancona, Vl, Giarre, G, DI GIOIA, E, Ciccarelli, P, Sarti, Cd, Balsotti, G, Pupita, P, Mincigrucci, M, Spadafora, A, Santeufemia, G, D'Andrea, A, Chiantera, A, Montemagno, U, Staiano, S, Arienzo, R, Pastore, Ar, Tamburrino, A, Colacurci, A, Izzo, S, Zumpano, N, Pascarella, A, DE SILVIO MG, DI PRISCO, L, Lauda, N, Sorrentino, O, Agrimi, C, Casarella, G, Pisaturo, G, Senatore, G, Ruccia, G, Fasolino, A, Tropea, P, Stigliano, Cm, Giannice, C, Vadala, P, Coco, A, Lombardo, R, Barese, G, Masciari, G, Pirillo, P, Gioffre, T, Ferruccio, C, Agostinelli, D, Tonti, Gc, Scopelliti, A, Schonauer, S, Bongiovanni, F, Tinelli, F, Poddi, Er, Scarpello, F, Colonna, L, Fischetti, G, Doria, R, Trombetta, G, Cocca, Eb, Carone, D, Nocera, F, Giambanco, V, Giannola, C, Graziano, R, Mezzatesta, M, Vegna, G, Giannone, G, Palumbo, G, Cancellieri, Francesco, Mondo, A, Cordopatri, A, Carrubba, M, Mazzola, V, Ettore, G, D'Asta, S, DI LIBERTO, P, Massacesi, A, DE ALOYSIO, P, Ognissanti, F, Gambacciani, A, Graziottin, A, Baldi, C, Colacurci, N, Parazzini, F, Chatenoud, L, and Chiaffarino, F.

Published
2001

16. Determinants of hysterectomy and oophorectomy in women attending menopause clinics in Italy

Author

DE ALOYSIO, D, DI DONATO, P, Giulini, Na, Modena, B, Cicchetti, G, Comitini, G, Gentile, G, Cristiani, P, Careccia, A, Esposito, E, Gigli, C, Mandruzzato, G, Petraglia, F, Bertelli, F, DEL FRATE, G, Garofalo, S, Marino, L, Costa, Mr, Quaranta, S, Bossi, Cm, Amantea, P, Omodei, U, Vaccari, M, Luerti, M, Repetti, F, Zandonini, G, Raspagliesi, F, Dolci, F, Zacchi, V, Bennici, S, Polizzotti, G, Bottino, S, Raffaelli, F, Minervini, C, Colombo, D, Belloni, C, Viani, A, Cecchini, G, Winkler, S, Samaja, Ba, Pasinetti, E, Penotti, M, Malanetto, C, Massobrio, M, Campagnoli, C, Dolfin, G, Tartaglino, P, Mossotto, D, Pesando, P, Pacilli, L, Rattazzi, Pd, Arisi, E, Gamper, M, Salvatores, D, Bocchin, E, Stellin, G, Meli, G, Azzini, V, Tirozzi, F, Buoso, G, Fraioli, R, Marsoni, V, Cetera, C, Sposetti, R, Bellati, U, Angeloni, C, Buonerba, M, Garzarelli, S, Santilli, C, Mucci, M, DI NISIO, Q, Falasca, L, Ferrante, D, Cirese, E, Todaro, Pa, Romanini, C, Spagnuolo, L, Lanzone, A, Donadio, C, Fabiani, M, Baldaccini, E, Votano, S, Serra, Gb, Bellardini, P, Massacesi, L, Donini, G, Genazzani, Ra, Scarselli, G, Curiel, P, DE LEO, V, Melani, A, D'Ancona, Vl, Giarre, G, DI GIOIA, E, Ciccarelli, P, Sarti, Cd, Balsotti, G, Pupita, P, Mincigrucci, M, Spadafora, A, Santeufemia, G, D'Andrea, A, Chiantera, A, Montemagno, U, Staiano, S, Arienzo, R, Pastore, Ar, Tamburrino, A, Colacurci, A, Izzo, S, Zumpano, N, Pascarella, A, DE SILVIO MG, DI PRISCO, L, Lauda, N, Sorrentino, O, Agrimi, C, Casarella, G, Pisaturo, G, Senatore, G, Ruccia, G, Fasolino, A, Tropea, P, Stigliano, Cm, Giannice, C, Vadala, P, Coco, A, Lombardo, R, Barese, G, Masciari, G, Pirillo, P, Gioffre, T, Ferruccio, C, Agostinelli, D, Tonti, Gc, Scopelliti, A, Schonauer, S, Bongiovanni, F, Tinelli, F, Poddi, Er, Scarpello, F, Colonna, L, Fischetti, G, Doria, R, Trombetta, G, Cocca, Eb, Carone, D, Nocera, F, Giambanco, V, Giannola, C, Graziano, R, Mezzatesta, M, Vegna, G, Giannone, G, Palumbo, G, Cancellieri, Francesco, Mondo, A, Cordopatri, A, Carrubba, M, Mazzola, V, Ettore, G, D'Asta, S, DI LIBERTO, P, Angeloni, D'Andrea, Stigliano, Arienzo, Donato, Di, Giulini, Gigli, Ricci, Marino, Luerti, Donini, Dolfin, Poddi, Santeufemia, Nocera, Melani, Messini, Mincigrucci, Salvatores, Bocchin, Massacesi, A, DE ALOYSIO, P, Ognissanti, F, Gambacciani, A, Graziottin, A, Baldi, C, Parazzini, F, Chatenoud, L, and Chiaffarino, F.

Published
2000

17. Epidemiology of acute promyelocytic leukemia in Italy

Author

Avvisati, G., primary, Mele, A., additional, Stazi, M.A., additional, Vegna, M.L., additional, Pasquini, P., additional, Mandelli, F., additional, Rotoli, B., additional, De Rosa, G., additional, Papa, G., additional, Venditti, A., additional, Citarrella, P., additional, Tambone Reyes, M., additional, Ascari, E., additional, Invernizzi, R., additional, Cajozzo, A., additional, Musso, M., additional, Alberti, A., additional, Peta, A., additional, Rossi Ferrini, P., additional, Leoni, F., additional, Caronia, F., additional, Mirto, S., additional, Nobile, F., additional, Iacopino, P., additional, Resegotti, L., additional, Allione, B., additional, Monfardini, S., additional, Zagonel, V., additional, Liso, V., additional, Specchia, G., additional, Tura, S., additional, Visani, G., additional, Broccia, G., additional, Deplano, W., additional, Ricciuti, F., additional, Pizzuti, M., additional, Longinotti, M., additional, Bonfigli, S., additional, De Laurenzi, A., additional, Pacilli, L., additional, Deriu, L., additional, Chierichini, A., additional, Bizzi, B., additional, Leone, G., additional, De Biasi, R., additional, Miraglia, E., additional, Bruzzese, L., additional, and Abbadessa, A., additional

Published
1991
Full Text
View/download PDF

18. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients.

Author

Franceschi M, Scarcelli C, Niro V, Seripa D, Pazienza AM, Pepe G, Colusso AM, Pacilli L, Pilotto A, Franceschi, Marilisa, Scarcelli, Carlo, Niro, Valeria, Seripa, Davide, Pazienza, Anna Maria, Pepe, Giovanni, Colusso, Anna Maria, Pacilli, Luigi, and Pilotto, Alberto

Abstract

Background: Drug use increases with advancing age, and in older patients it is associated with an increase in adverse drug reactions (ADRs). ADRs are a primary cause of morbidity and mortality worldwide.Objectives: To evaluate the prevalence, clinical characteristics and avoidability of ADR-related hospital admissions in elderly patients.Methods: From November 2004 to December 2005, all patients aged >or=65 years consecutively admitted to the Geriatric Unit of the Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo in Italy, were evaluated for enrolment in the study. ADRs were defined according to the WHO Adverse Reaction Terminology system. Drugs were classified according to Anatomical Therapeutic Chemical classification system. The Naranjo algorithm was used to evaluate the relationship between drug use and the ADR (definite, probable, possible or doubtful) and Hallas criteria were used to evaluate the avoidability of the ADR (definitely avoidable, possibly avoidable or unavoidable). All cases of a suspected ADR were discussed by a team trained in drug safety, including three geriatricians, one clinical pharmacologist and one pharmacist. Only cases of an ADR with an agreement >or=80% were included.Results: Of the 1756 patients observed, 102 (5.8%, 42 males, 60 females, mean age 76.5 +/- 7.4 years, range 65-93 years) showed certain (6.8%) or probable (91.2%) ADR-related hospitalization. Gastrointestinal disorders (48 patients, 47.1%); platelet, bleeding and clotting disorders (20 patients, 19.6%); and cardiovascular disorders (13 patients, 12.7%) were the most frequent ADRs. NSAIDs (23.5%), oral anticoagulants (20.6%), low-dose aspirin (acetylsalicylic acid) [13.7%] and digoxin (12.7%) were the drugs most frequently involved in ADRs. Of the ADRs, 45.1% were defined as definitely avoidable, 31.4% as possibly avoidable, 18.6% as unavoidable and 4.9% as unclassifiable. Of 78 patients with definitely or possibly avoidable ADRs, 17 patients (21.8%) had received an inappropriate prescription, 29 patients (37.2%) had not received a prescription for an effective gastroprotective drug concomitantly with NSAID or low-dose aspirin treatment and 32 patients (41%) were not monitored during drug treatment.Conclusion: In the elderly, almost 6% of hospitalizations are ADR related. Most of these ADRs are potentially avoidable. Strategies that reduce inappropriate prescriptions and monitoring errors, as well as improving active prevention of ADRs, are needed in elderly subjects. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

21. General and medical factors associated with hormone replacement therapy among women attending menopause clinics in Italy

Author

Aloysio, D., Di Donato, P., Giulini, N. A., Modena, B., Cicchetti, G., Comitini, G., Gentile, G., Cristiani, P., Careccia, A., Esposito, E., Gigli, C., Mandruzzato, G., Petraglia, F., Bertelli, F., Del Frate, G., Garofalo, S., Marino, L., Costa, M. R., Qaranta, S., Bossi, C. M., Amantea, P., Omodei, U., Vaccari, M., Luerti, M., Repetti, F., Zandonini, G., Raspagliesi, F., Dolci, F., Zacchi, V., Bennici, S., Polizzotti, G., Bottino, S., Raffaelli, F., Minervini, C., Colombo, D., Belloni, C., Viani, A., Cecchini, G., Winkler, S., Samaja, B. A., Pasinetti, E., Penotti, M., Malanetto, C., Massobrio, M., Campagnoli, C., Dolfin, G., Tartaglino, P., Mossotto, D., Pesando, P., Pacilli, L., Rattazzi, P. D., Arisi, E., Gamper, M., Salvatores, D., Bocchin, E., Stellin, G., Meli, G., Azzini, V., Tirozzi, F., Buoso, G., Fraioli, R., Marsoni, V., Cetera, C., Sposetti, R., Bellati, U., Angeloni, C., Buonerba, M., Garzarelli, S., Santilli, C., Mucci, M., Di Nisio, Q., Falasca, L., Ferrante, D., Cirese, E., Todaro, P. A., Romanini, C., Spagnuolo, L., Lanzone, A., Donadio, C., Fabiani, M., Baldaccini, E., Votano, S., Serra, G. B., Bellardini, P., Massacesi, L., Donini, G., Genazzani, R. A., Scarselli, G., Curiel, P., Vincenzo De Leo, Melani, A., Levi D Ancona, V., Giarrè, G., Di Gioia, E., Ciccarelli, P., Donati Sarti, C., Balsotti, G., Pupita, P., and Parazzini, F.

22. Risk factors for genital prolapse in non-hysterectomized women around menopause - Results from a large cross-sectional study in menopausal clinics in Italy

Author

Aloysio, D., Di Donato, P., Giulini, Na, Modena, B., Cicchetti, G., Comitini, G., Gentile, G., Cristiani, P., Careccia, A., Esposito, E., Gigli, C., Mandruzzato, G., Petraglia, F., Bertelli, F., Del Frate, G., Garofalo, S., Marino, L., Costa, MR, Quaranta, S., Bossi, Cm, Amantea, P., Omodei, U., Vaccari, M., Luerti, M., Repetti, F., Zandonini, G., Raspagliesi, F., Dolci, F., Zacchi, V., Bennici, S., Polizzotti, G., Bottino, S., Raffaelli, F., Minervini, C., Colombo, D., Belloni, C., Viani, A., Cecchini, G., Winkler, S., Samaja, Ba, Pasinetti, E., Penotti, M., Malanetto, C., Massobrio, M., Campagnoli, C., Dolfin, G., Tartaglino, P., Mossotto, D., Pesando, P., Pacilli, L., Rattazzi, Pd, Arisi, E., Gamper, M., Salvatores, D., Bocchin, E., Stellin, G., Meli, G., Azzini, V., Tirozzi, F., Buoso, G., Fraioli, R., Marsoni, V., Cetera, C., Sposetti, R., Bellati, U., Angeloni, C., Buonerba, M., Garzarelli, S., Santilli, C., Mucci, M., Di Nisio, Q., Falasca, L., Ferrante, D., Cirese, E., Todaro, Pa, Romanini, C., Spagnuolo, L., Lanzone, A., Donadio, C., Fabiani, M., Baldaccini, E., Votano, S., Serra, Gb, Bellardini, P., Massacesi, L., Donini, G., Genazzani, Ra, Scarselli, G., Curiel, P., Leo, V., Melani, A., D Ancona, Vl, Giarre, G., Di Gioia, E., Ciccarelli, P., Sarti, Cd, Balsotti, G., Pupita, P., Mincigrucci, M., Spadafora, A., Santeufemia, G., D Andrea, A., Chiantera, A., Montemagno, U., Staiano, S., Arienzo, R., Pastore, Ar, Tamburrino, A., Colacurci, A., Izzo, S., Zumpano, N., Pascarella, A., Silvio, Mg, Di Prisco, L., Lauda, N., Sorrentino, O., Agrimi, C., Casarella, G., Pisaturo, G., Senatore, G., Ruccia, G., Fasolino, A., Tropea, P., Stigliano, Cm, Giannice, C., Vadala, P., Coco, A., Lombardo, R., Barese, G., Masciari, G., Pirillo, P., Gioffre, T., Ferruccio, C., Agostinelli, D., Tonti, Gc, Scopelliti, A., Schonauer, S., Bongiovanni, F., Tinelli, F., Poddi, Er, Scarpello, F., Colonna, L., Fischetti, G., Doria, R., Trombetta, G., Cocca, Eb, Carone, D., Nocera, F., Giambanco, V., Giannola, C., Graziano, R., Mezatesta, M., Vegna, G., Giannone, G., Palumbo, G., Cancellieri, F., Mondo, A., Cordopatri, A., Carrubba, M., Mazzola, V., Ettore, G., D Asta, S., Di Liberto, P., Massacesi, A., Aloysio, P., Ognissanti, F., Gambacciani, A., Graziottin, A., Baldi, C., Parazzini, F., Chatenoud, L., and Francesca Chiaffarino

23. Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study

Author

Pagano, L., Valentini, Cg, Di Paolantonio, G., Melillo, L., Gaidano, G., Venditti, A., Specchia, G., Cattaneo, C., Pica, G., Spadea, A., D’arco, A., Candoni, A., Rodeghiero, F., Abbadessa, A., Piccin, A., Ballerini, F., Sorasio, R., Nosari, A., Caramatti, C., Invernizzi, R., Aversa, F., Pacilli, L., Musto, P., Peli, A., Quintini, G., Forghieri, F., Facchetti, F., Pavan, L., Mannelli, F., Massimiliano BONIFACIO, Leone, G., and Pulsoni, A.

Subjects
blastic plasmacytoid dendritic leukemia, rare disease, chemotherapy

25. Epidemiology of acute promyelocytic leukemia in Italy

Author

Rotoli, B., De Rosa, G., Papa, G., Venditti, A., Citarrella, P., Tambone Reyes, M., Ascari, E., Invernizzi, R., Cajozzo, A., Musso, M., Alberti, A., Peta, A., Rossi Ferrini, P., Leoni, F., Caronia, F., Mirto, S., Nobile, F., Iacopino, P., Resegotti, L., Allione, B., Monfardini, S., Zagonel, V., Liso, V., Specchia, G., Tura, S., Visani, G., Broccia, G., Deplano, W., Ricciuti, F., Pizzuti, M., Longinotti, M., Bonfigli, S., De Laurenzi, A., Pacilli, L., Deriu, L., Chierichini, A., Bizzi, B., Leone, G., De Biasi, R., Miraglia, E., Bruzzese, L., Abbadessa, A., Avvisati, G., Mele, A., Stazi, M.A., Vegna, M.L., Pasquini, P., and Mandelli, F.

Published
1991
Full Text
View/download PDF

26. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

D. Ielo, Mario Cazzola, A. De Vivo, Mario Petrini, G. Fioritoni, Simona Sica, Fausto Castagnetti, B. Falini, Miriam Fogli, Agostino Cortelezzi, C. Viganò, Giuliana Alimena, Maurizio Musso, G. Spinosa, Flavia Salvi, Giancarlo Latte, Michele Pizzuti, Nicola Cantore, D. Luzzi, B. Ronci, Francesco Merli, Mario Boccadoro, Diamante Turri, Monica Bocchia, Patrizia Tosi, A. M. Carella, Simona Luatti, G. Semenzato, Mariella Grasso, Nicoletta Testoni, Giovanni Martinelli, Ester Pungolino, Giuseppe Tagariello, A. Russo Rossi, Simona Soverini, Francesca Ronco, Franco Iuliano, Giovanni Rosti, Alberto Bosi, Tamara Intermesoli, Dario Ferrero, Sara Galimberti, Giovanna Rege-Cambrin, Ferdinando Porretto, Sabina Russo, Roberto Latagliata, Pellegrino Musto, E. Morra, Agostino Tafuri, Franca Falzetti, Francesco Cavazzini, P. Galieni, Marzia Salvucci, F. Rodighiero, Stefana Impera, Fausto Dore, P. De Fabritiis, V. Meneghini, Elisabetta Calistri, Paolo Vigneri, Ivana Pierri, Michele Cavo, Massimo Pini, Fabrizio Ciccone, Domenico Russo, E Trabacchi, Franco Gherlinzoni, Michele Baccarani, Ilaria Iacobucci, Roberto Sartori, Paolo Avanzini, D. Noli, Roberto Marasca, Simonetta Pardini, A. Malpignano, Maria Concetta Petti, Bruno Martino, M. Bergamaschi, Giovanni Pizzolo, Valeria Santini, E Orlandi, Catia Bigazzi, Serena Rupoli, Giuseppe Saglio, I. Cervello, Clementina Caracciolo, Anna Merli, R. Di Lorenzo, Enrico Pogliani, Francesco Lanza, Mariella Girasoli, M. Apolinari, Caterina Musolino, Francesco Fabbiano, D. Vallisa, Mario Annunziata, Gabriele Gugliotta, V. De Stefano, Ignazio Majolino, Sergio Storti, P. Leoni, Adele Capucci, Massimo Breccia, Alessandro Isidori, Carmen Fava, Gianni Binotto, Carlo Gambacorti-Passerini, L. Pacilli, Mario Tiribelli, Luciano Levato, Felicetto Ferrara, N. Di Renzo, Anna D'Emilio, Francesco Pisani, Fabio Stagno, Monica Crugnola, M. Trawiska, Patrizia Pregno, Marzia Defina, Stefano Molica, Mario Luppi, Michele Malagola, Davide Rapezzi, A. M. Liberati, E. De Biasi, A. Iurlo, Umberto Vitolo, Silvana Capalbo, Maria Teresa Bochicchio, F. Di Raimondo, Franco Aversa, Giuseppe Visani, Fausto Palmieri, Alessandro Rambaldi, Sergio Siragusa, Massimiliano Bonifacio, Luigiana Luciano, Giorgina Specchia, Elisabetta Abruzzese, A. De Blasio, Francesco Albano, Antonio Cuneo, Emilio Usala, Alfonso Zaccaria, R Fanin, Francesca Palandri, Fabrizio Pane, Enrico Montefusco, A. Gozzini, Giulio Rossi, Emanuele Angelucci, A. Bacigalupo, Marco Gobbi, Michele Cedrone, Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., on behalf of the, GIMEMA CML Working Party [.., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, M.T., Apolinari, M., Fogli, M., Cervello, I., ]., Castagnetti, Fausto, De Vivo, A., Pane, Fabrizio, Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Bochicchio, M. T., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, S. F., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, A. M., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, E. M., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, M. C., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, A. M., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., D'Emilio, A., Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, and D'Emilio, A

Subjects
Male, Pediatrics, Host response, BCR-ABL, Chronic myeloid leukemia, Prognosis, Tyrosine kinase inhibitors, Young adults, Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Middle Aged, Prospective Studies, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Spleen, Splenomegaly, Young Adult, Oncology, Hematology, Tyrosine kinase inhibitor, Disease, Antineoplastic Agent, Tyrosin kinase inhibitor, Protein-Tyrosine Kinase, hemic and lymphatic diseases, 80 and over, Age Factor, Young adult, Chronic, Leukemia, Incidence (epidemiology), Myeloid leukemia, bcr-abl1, chronic myeloid leukemia, prognosis, tyrosine kinase inhibitors, young adults, Human, medicine.medical_specialty, Prognosi, Protein Kinase Inhibitor, NO, medicine, Adult patients, business.industry, medicine.disease, Clinical trial, Prospective Studie, Medicine (all), Immunology, BCR-ABL Positive, BCR-ABL, chronic myeloid leukemia, prognosis, tyrosine kinase inhibitors, young adults, business, Myelogenous
Abstract

BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). CONCLUSIONS: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome. CLINICAL TRIAL NUMBERS: NCT00510926, NCT00514488, NCT00769327, NCT00481052. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Published
2015

27. Promyelocytic sarcoma of the spine: a case report and review of the literature.

Author

Pacilli L, Lo Coco F, Ramadan SM, Giannì L, Pingi A, Remotti D, and Majolino I

Abstract

Myeloid sarcoma (MS, previously named granulocytic sarcoma or chloroma) is a rare extramedullary tumour of immature myeloid cells. It can be present before, concurrently with, or after the diagnosis of acute myeloid leukemia. MS is extremely uncommon in acute promyelocytic leukemia (APL). In the case described here, MS was the sole site of APL relapse and the cause of spinal cord compression. The patient presented with neurologic symptoms due to a paravertebral mass of MS after 7 years of complete remission. He was treated with excision of the mass followed by local radiotherapy. Systemic treatment was also given with combined arsenic trioxide and all-trans retinoic acid and the patient was able to achieve a second prolonged clinical and molecular remission.

Published
2010
Full Text
View/download PDF

28. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto).

Author

Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, Cenacchi A, Pacilli L, Fabbiano F, and Del Favero A

Subjects
Adolescent, Adult, Aged, Antifungal Agents therapeutic use, Cardiomyopathies microbiology, Central Nervous System Diseases microbiology, Female, Fever etiology, Humans, Intestinal Diseases microbiology, Liver Diseases microbiology, Lung Diseases, Fungal complications, Male, Middle Aged, Mucormycosis drug therapy, Nasopharyngeal Diseases microbiology, Neutropenia complications, Orbital Diseases microbiology, Prognosis, Retrospective Studies, Hematologic Neoplasms complications, Mucormycosis complications, Opportunistic Infections complications
Abstract

A retrospective study of 37 patients with haematological malignancy (21 acute myeloid leukaemia, 11 acute lymphoid leukaemia, two lymphoma, two hairy cell leukaemia, one Hodgkin's disease) and histologically documented mucormycosis was conducted to evaluate the clinical characteristics and ascertain the factors which influenced the outcome from mycotic infection. Patients were admitted to 18 haematology divisions in tertiary care or university hospitals in Italy between 1987 and 1995. Fever, thoracic pain, dyspnoea and cough were the most frequent presenting symptoms. At the onset, 89% patients were neutropenic (neutrophil counts < 0.5 x 10(9)/l) with a median duration of previous neutropenia of 14 d (range 6-60). The most frequent sites of infection were lungs (81%), CNS (27%), sinus (16%), liver (16%) and orbital space (10%). Only three patients were asymptomatic. A correct in vivo diagnosis was made in only 13 (35%) patients. When performed, thoracic and cranial CT scan were the most useful diagnostic investigations. Despite the fact that 26 febrile patients were treated with empirical antifungal treatment, 28 of the 37 patients (76%) died from fungal infection at a median time of 17 d from the onset of clinical symptoms. Nine patients were cured by antifungal therapy plus, in five cases, radical surgery procedures. An analysis of factors influencing outcome demonstrated that the resolution of chemotherapy-induced neutropenia and prolonged treatment with amphotericin B and, if feasible, radical surgical debridement treatment, were significantly correlated with recovery from infection. Mucormycosis, a rare filamentous fungal infection that occurs most frequently in neutropenic acute leukaemia patients, is characterized by a high mortality rate. Extensive and aggressive diagnostic and therapeutic procedures are essential to improve the prognosis in these patients.

Published
1997
Full Text
View/download PDF

29. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.

Author

De Laurenzi A, Iudicone P, Zoli V, De Rosa L, Guglielmetti M, Pescarollo A, Papetti C, Pacilli L, Lapponi P, and Petti N

Subjects
Adolescent, Adult, Bone Marrow Transplantation, Child, Cytotoxicity Tests, Immunologic, Feasibility Studies, Female, Hematopoietic Stem Cells drug effects, Humans, Interleukin-2 adverse effects, Leukemia blood, Leukemia immunology, Leukemia, Myeloid, Acute blood, Leukemia, Myeloid, Acute immunology, Leukemia, Myeloid, Acute therapy, Lymphoma, Non-Hodgkin blood, Lymphoma, Non-Hodgkin immunology, Male, Middle Aged, Multiple Myeloma blood, Multiple Myeloma immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Recombinant Fusion Proteins adverse effects, Recombinant Fusion Proteins therapeutic use, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Interleukin-2 therapeutic use, Leukemia therapy, Lymphoma, Non-Hodgkin therapy, Multiple Myeloma therapy
Abstract

Autologous bone marrow transplantation (ABMT) for hematologic malignancies is associated with a high relapse rate. Interleukin-2 (IL-2) administration is a therapy that may prevent relapse if used when the tumor burden is minimal. In this study we administered recombinant IL-2 (rIL-2) therapy to 12 patients affected by hematologic malignancies either before or after autologous stem cell transplantation (ASCT). rIL-2 was given by a 6 day continuous intravenous infusion with escalating doses, up to 18 x 10(6)/m2/day, depending on patient tolerance. The functional immune responses of the patients were assessed as natural killer (NK) and lymphokine-activated killer (LAK) cytotoxic activities and in vitro interferon-gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) synthesis. During rIL-2 treatment, the expected side effects occurred; only 3 patients, who showed severe cardiovascular toxicity, required suspension of the treatment. All toxicities reversed after the end of the therapy. Immunologic monitoring was carried out the day before starting rIL-2 infusion and then repeated on days 3, 7, and 14 after rIL-2 was discontinued. Following every rIL-2 course, a pronounced increase in CD3+, CD8+, CD56+ cells was found, with a peak value on day 3. The NK and LAK activities showed a significant increase on day 3 (p < 0.001) over pretherapy values; the increase lasted until day 14, although the difference at later time points was not significant. Before transplant the synthesis of both IFN-gamma and TNF-alpha decreased following rIL-2 therapy, whereas higher levels of these lymphokines were found after posttransplant rIL-2 courses.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1995
Full Text
View/download PDF

30. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.

Author

Montuoro A, De Rosa L, De Blasio A, Pacilli L, Petti N, and De Laurenzi A

Subjects
Adult, Aged, Female, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Male, Melphalan administration & dosage, Middle Aged, Multiple Myeloma mortality, Multiple Myeloma pathology, Prednisone administration & dosage, Recombinant Proteins, Remission Induction, Time Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Interferon-alpha therapeutic use, Multiple Myeloma therapy
Abstract

Alpha-2a-interferon (IFN) has demonstrable activity in advance and refractory multiple myeloma (MM), because of the in vitro synergism between IFNs and cytotoxic agents we report the preliminary results of a therapeutic trial of 50 patients with MM. Twenty-eight patients were randomized to receive melphalan plus prednisone (MP) and 22 were randomized to receive IFN plus MP (IFN-MP). Criteria for response, progression and relapse were those of the Southwestern Oncology Group. 95% of the patients receiving IFN-MP responded to therapy as opposed to 68% of the patients receiving MP (P less than 0.05). Response was independent of M-component immunoglobulin class but in stage III it was higher in the IFN-MP group than in the MP group (P less than 0.05). The combination IFN-MP was well tolerated without unusual or unexpected toxic effects. The response duration time was longer in the IFN-MP group than in the MP group (P less than 0.025). The median survival was 80 weeks in the MP group and in the IFN-MP group the 93% of patients were still alive after 90 weeks (P less than 0.025). Our results show that the use of the IFN as an adjuvant to MP improves the percentage of responders, the response duration time and the median survival of untreated patients with MM.

Published
1990
Full Text
View/download PDF

31. Empiric antibiotic and antifungal therapy for granulocytopenic patients with acute leukemia.

Author

De Rosa L, Montuoro A, De Blasio A, Della Seta R, Pacilli L, Pescador L, Petti N, and De Laurenzi A

Subjects
Acute Disease, Adolescent, Adult, Aged, Aged, 80 and over, Aminoglycosides, Bacterial Infections drug therapy, Child, Drug Therapy, Combination, Female, Humans, Lactams, Leukemia, Myeloid complications, Male, Middle Aged, Mycoses drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Prospective Studies, Agranulocytosis etiology, Anti-Bacterial Agents administration & dosage, Antifungal Agents administration & dosage, Leukemia complications
Abstract

A prospective study was undertaken to determine the effectiveness of an empiric antibiotic treatment employing the combination of a beta-lactam and an aminoglycoside followed in non responders by vancomycin and amphotericin B after 48 and 96 hours respectively. We have evaluated 180 febrile episodes in 102 granulocytopenic leukemic patients. Febrile episodes (44%) were microbiologically documented; 29% were only clinically documented and 27% were possible. In the 180 evaluable episodes treated with a beta-lactam and an aminoglycoside the overall response rate was 61%. In non responders the addition of vancomycin increased the response rate to 83% and the subsequent addition of amphotericin B moved the total responders to 96%. Antibiotic related side effects were minimal. These data suggest the importance of an empiric strategy for treatment of bacterial infections arising in granulocytopenic patients. An early empiric antifungal therapy also appears necessary to control clinically undetected fungal invasion.

Published
1990

33. [Special obstetrico-gynecologic hospital structure and local service units. Considerations on the availability and need for ULS 35 and 36].

Author

Pacilli L, Arrotta S, Panazzolo A, Ansaldi E, Graffino W, Napoli F, and Bergantino L

Subjects
Health Services Accessibility, Health Services Needs and Demand, Humans, Italy, Community Health Services, Hospital Departments, Hospitals, Maternity, Hospitals, Special, Obstetrics and Gynecology Department, Hospital
Abstract

The underlying principles of the national health reform measures and those approved by the Piedmont Region's programmes with regard to social and health reorganisation are recalled. Reference is made to anomalies with respect to local health services No. 35 and No. 36 in the case of obstetrics and gynaecology, there being three maternity departments for 97,251 inhabitants in the area concerned. The main aspects of the division are examined. It is shown that implementation will only be possible if there is a usership capable of feeding every branch of the structure set up. It is suggested that the specialist activities of obstetrics and gynaecology be concentrated at Susa and Avigliana, though oven this division will not ensure a proper flow of users. The position could be improved by better employment of the basic structures, i.e. the consulting surgeries and SAUB out-patient departments.

Published
1980

34. [Lysosomal enzymes in neoplastic pathology of the cervix uteri. Study of acid phosphatase, as a diagnostic test, in vaginal secretions of patients with pre-invasive and invasive carcinoma of the cervix].

Author

Panazzolo A, Bergantino L, Arrotta S, Napoli F, and Pacilli L

Subjects
Adult, Aged, Female, Humans, Middle Aged, Uterine Cervical Neoplasms enzymology, Vaginal Smears, Acid Phosphatase analysis, Lysosomes enzymology, Uterine Cervical Neoplasms diagnosis, Vagina enzymology
Published
1978

35. Combination chemotherapy for marrow relapse in children and adolescents with acute lymphocytic leukaemia.

Author

Amadori S, Spiriti MA, Meloni G, Pacilli L, Papa G, and Mandelli F

Subjects
Adolescent, Antineoplastic Agents adverse effects, Child, Child, Preschool, Daunorubicin administration & dosage, Drug Therapy, Combination, Female, Humans, Male, Prednisone administration & dosage, Recurrence, Vincristine administration & dosage, Antineoplastic Agents administration & dosage, Leukemia, Lymphoid drug therapy
Abstract

38 children with acute lymphocytic leukaemia (ALL) in haematologic relapse were retreated with vincristine, daunomycin and prednisone (VPD) together with intrathecal methotrexate and prednisone, followed by asparaginase in those patients not in complete remission after 4 weeks. The overall complete remission (CR) rate was 79%; asparaginase was needed to achieve CR in 7 of the 30 responding patients. The median duration of second remission was only 36 weeks, but 6 out of 15 children receiving the COAP-POMP-CART consolidation regimen remain in continuous second remission after 37-260 weeks; 3 of them are currently off all therapy. It is concluded that a prolonged second remission can be achieved in children with ALL in bone marrow relapse by combining intensive chemotherapy with the prevention of meningeal leukaemia.

Published
1981
Full Text
View/download PDF

36. Therapy of acute nonlymphocytic leukemia in children: a review of 73 patients.

Author

Amadori S, Petti MC, Pacilli L, Papa G, and Mandelli F

Subjects
Adolescent, Adult, Asparaginase administration & dosage, Carmustine administration & dosage, Child, Child, Preschool, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Daunorubicin administration & dosage, Doxorubicin administration & dosage, Drug Therapy, Combination, Female, Humans, Infant, Leukemia, Myeloid, Acute mortality, Male, Methotrexate administration & dosage, Thioguanine administration & dosage, Vincristine administration & dosage, Whole-Body Irradiation, Antineoplastic Agents administration & dosage, Leukemia, Myeloid, Acute therapy
Abstract

Since 1969, 73 children with acute nonlymphocytic leukemia have been admitted for evaluation and treatment at the Institute of Hematology of the University of Rome. Various drug regimens, basically including daunomycin and/or cytosine arabinoside, were employed both for induction and maintenance treatment. Overall, the incidence of complete remission was 63%. The availability of intensive supportive measures starting in 1974 appears to be the most likely explantation for the higher response rate observed since then. Duration of remission and overall survival were disappointingly short owing to the high frequency of bone marrow relapse. Carefully controlled clinical studies will in the future be necessary to explore better methods of preventing leukemic relapse.

Published
1981
Full Text
View/download PDF

39. [Neonatal malformations and hormone therapy during pregnancy].

Author

Pacilli L, Graffino W, and Arrotta S

Subjects
Adult, Brain abnormalities, Cleft Palate chemically induced, Estrogens adverse effects, Female, Heart Defects, Congenital chemically induced, Hernia chemically induced, Humans, Infant, Newborn, Limb Deformities, Congenital, Pregnancy, Progesterone adverse effects, Urogenital Abnormalities, Abnormalities, Drug-Induced, Contraceptives, Oral adverse effects, Gonadal Steroid Hormones adverse effects, Progestins adverse effects
Published
1981

40. Plasma cell leukemia: a report on three patients.

Author

Pacilli L, Ferraro P, Cochi S, and De Laurenzi A

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chlorambucil administration & dosage, Cyclophosphamide administration & dosage, Female, Humans, Leukemia, Plasma Cell mortality, Leukemia, Plasma Cell therapy, Male, Melphalan administration & dosage, Middle Aged, Multiple Myeloma complications, Prednisone administration & dosage, Time Factors, Vincristine administration & dosage, Whole-Body Irradiation, Leukemia, Plasma Cell diagnosis
Abstract

Three patients with plasma cell leukemia are reported. Two of them has a previous history of myeloma; the third one started with a plasma cell leukemia. Diagnosis was made from the required presence of 20% plasma cells in the peripheral blood. In all 3 cases, bone marrow aspiration and peripheral blood showed plasma cells strongly positive for acid phosphatase and alpha-naphthyl acetate esterase, and negative for periodic acid-Schiff. The first patient was treated with a polychemotherapy regimen that included vincristine, cyclophosphamide, chlorambucil and prednisone, and the second patient with melphalan and prednisone; the third one, who started with plasma cell leukemia, received total body irradiation at the dose of 600 rad. The results of the therapy and survival time, which was never more than 3 months, are in accord with other reports in the literature.

Published
1983
Full Text
View/download PDF

41. Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia.

Author

Amadori S, Tribalto M, Pacilli L, De Laurentis C, Papa G, and Mandelli F

Subjects
Acute Disease, Adolescent, Adult, Asparaginase adverse effects, Child, Child, Preschool, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Leukemia diagnosis, Leukemia, Lymphoid drug therapy, Male, Methotrexate adverse effects, Middle Aged, Asparaginase administration & dosage, Leukemia drug therapy, Methotrexate administration & dosage
Abstract

Seventy-six patients with advanced acute leukemia refractory to conventional chemotherapy were treated with a sequential combination of methotrexate (MTX) and L-asparaginase (L-ASP), based on the reported schedule-dependent synergism between the two drugs in human leukemic cells in vitro. On Day 1, patients received 60 mg/m2 of MTX iv, followed 24 hours later by L-ASP at a dose of 10,000 IU/m2 iv. This sequence was repeated weekly with 50% escalations in the dose of MTX with each course. Overall, 31 of 76 patients (40.7%) achieved complete remission after a median of three courses; the response rate was 35.5% in patients with acute nonlymphocytic leukemia (21 of 59 patients) and 58.8% in patients with acute lymphocytic leukemia (ten of 17). Increasing the starting dose of MTX to 200 mg/m2 did not improve the response rate. Maintenance therapy with the same combination given every 2 weeks produced a median complete remission of 10 weeks. Toxicity was manifested by: acute hypersensitivity reactions to L-ASP (five patients), stomatitis (36 patients), and mild liver abnormalities (five patients). MTX in doses up to 200 mg/m2 caused minimal myelosuppression. We conclude that the MTX-L-ASP combination is a well-tolerated, highly effective induction regimen for refractory acute leukemia.

Published
1980

43. Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia.

Author

Amadori S, Papa G, Meloni G, Pacilli L, and Mandelli F

Subjects
Acute Disease, Adolescent, Adult, Aged, Child, Child, Preschool, Cytarabine administration & dosage, Cytarabine adverse effects, Daunorubicin administration & dosage, Daunorubicin adverse effects, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Leukemia mortality, Male, Middle Aged, Thioguanine administration & dosage, Thioguanine adverse effects, Antineoplastic Agents administration & dosage, Leukemia drug therapy
Published
1979
Full Text
View/download PDF

45. Preliminary results of the combination methotrexate-asparaginase in patients with acute non lymphoid leukemia.

Author

Mandelli F, Amadori S, Pacilli L, and Tribalto M

Subjects
Adolescent, Adult, Asparaginase administration & dosage, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Male, Methotrexate administration & dosage, Asparaginase therapeutic use, Leukemia drug therapy, Methotrexate therapeutic use
Abstract

Twenty-three refractory and/or relapsing acute non-lymphoid leukemia patients were treated with a combination of methotrexate (MTX) and asparaginase (Aase) slightly modifed from that recently proposed by Capizzi et al. Patients received MTX on day 1, followed by Aase 24 hours later; the two day course was repeated weekly. The starting dose of MTX was 60 mg/m2 and was increased by 50% at each course to maximum toxicity. The dose of Aase was kept constant at 10,000 u/m2. Twelve patients achieved complete remission lasting 3 to 58 weeks, with 8 patients surviving more than 30 weeks. Toxicity has been remarkably mild with the major problem being hypersensitivity to Aase.

Published
1978

47. Discontinuing therapy in childhood acute lymphocytic leukemia. A multicentric survey in Italy.

Author

Mandelli F, Amadori S, Rajnoldi AC, Di Montezemolo LC, Madon E, Masera G, Meloni G, Pacilli L, Paolucci G, Pastore G, Rosito P, Uderzo C, and Vecchi V

Subjects
Adolescent, Child, Child, Preschool, Female, Humans, Infant, Male, Neoplasm Recurrence, Local epidemiology, Prognosis, Remission, Spontaneous, Risk, Time Factors, Leukemia, Lymphoid therapy
Abstract

The results of discontinuing therapy in children with acute lymphocytic leukemia observed at four associated institutions are presented. Of the 247 patients who achieved complete remission, 122 (49.3%) reached the point of discontinuing therapy after 2-4 years of continuous remission. The median period off therapy was 13 months with a range of 1-69 months. Of the 122 children removed from therapy, 27 (22.1%) relapsed, mainly in the bone marrow; relapses occurred 1-32 months after cessation of therapy (median ten months) with only two relapses occurring later than two years. By actuarial analysis, 57% of the patients are projected in continuous remission after five years from cessation of therapy. Neither selected features at diagnosis nor single modalities of treatment were found to predict whether relapse would occur after discontinuing therapy. Long-term remission and possibly cure can be expected in over one-third of newly diagnosed children with ALL after 2-4 years of antileukemic treatment.

Published
1980
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results